Neuroleptic induced parkinsonism
ICD-10 G21.11 is a billable code used to indicate a diagnosis of neuroleptic induced parkinsonism.
Neuroleptic induced parkinsonism is a type of drug-induced movement disorder characterized by symptoms similar to those of Parkinson's disease, resulting from the use of neuroleptic medications, which are primarily used to treat psychiatric disorders. Patients may present with bradykinesia, rigidity, tremors, and postural instability. The condition arises due to the blockade of dopamine receptors in the nigrostriatal pathway, leading to an imbalance in the dopaminergic and cholinergic systems. Symptoms can develop shortly after the initiation of neuroleptic therapy or after dosage increases. While the condition is often reversible upon discontinuation or reduction of the neuroleptic medication, some patients may experience persistent symptoms. It is crucial for healthcare providers to differentiate neuroleptic induced parkinsonism from idiopathic Parkinson's disease and other extrapyramidal disorders to ensure appropriate management and treatment. The diagnosis is primarily clinical, supported by patient history and response to medication adjustments.
Detailed records of medication prescribed, dosages, and patient responses.
Patients presenting with new-onset movement disorders after starting or increasing neuroleptic medications.
Consideration of alternative treatments and monitoring for side effects.
Comprehensive neurological assessments and differentiation from other movement disorders.
Patients with a history of neuroleptic use presenting with parkinsonian symptoms.
Need for thorough evaluation to rule out other causes of parkinsonism.
Used for follow-up visits to assess symptoms and medication adjustments.
Document patient history, medication changes, and symptom assessment.
Psychiatric and neurological evaluations may require additional documentation.
The primary symptoms include bradykinesia, rigidity, tremors, and postural instability, which are similar to those seen in idiopathic Parkinson's disease.
Differentiation is based on the patient's medication history, the timing of symptom onset in relation to neuroleptic use, and the response to medication adjustments.
